BACKGROUND Recurrent vulvovaginal candidiasis (VVC) remains a challenge to manage in clinical practice. Recent epidemiologic studies indicate that non-albicans Candida spp. are more resistant to conventional antifungal treatment with azoles and are considered as causative pathogens of vulvovaginal candidiasis. METHODS We searched PubMed and Scopus for studies that reported clinical evidence o...

BACKGROUND The optimal treatment algorithm for noncutaneous melanomas must yet be established. OBJECTIVE To compare systemic treatment-relevant mutational status, metastatic pattern and response to systemic treatment in noncutaneous melanoma. METHODS Retrospective single-center study analyzing 64 noncutaneous melanoma patients treated between January 2006 and September 2013. RESULTS c-KIT...

recurrent vulvovaginal candidiasis (rvvc) is seen in 5% of women with candida vaginitis. use of fluconazole as prophylactic treatment has been suggested for rvvc. the aim of the present study was to evaluate the efficacy of fluconazole suppressive therapy in rvvc patients, as a randomized, placebo-controlled, double-blind prophylactic study. among the 330 women with acute symptomatic vulvovagin...

La candidiasis vulvovaginal es una enfermedad ocasionada por las especies de Cándida, principalmente Candida albicans, la cual puede ser colonizante microflora vaginal mujeres saludables, sin provocar enfermedad. Es segunda causa más frecuente vaginitis, solo superada vaginosis bacteriana. Por su alta prevalencia, razones frecuentes consulta ginecológica. Afecta a en edad reproductiva, y hasta ...

Background. Lichen Planus is a chronic mucocutaneous disease of immunological basis and unknown etiology. women with oral lichen planus may have concomitant manifestations in vulvovaginal areas. Objective. To determine the frequency and risk factors of genital involvement in a group of Iranian women affected by oral lichen planus. Methods. Thirty-six women with clinical and histopathological di...

In a multicenter, randomized, invesgtigator-blind, parallel study, 398 patients were dispensed topical butoconazole nitrate 2% cream for 3 days (n = 199) or miconazole nitrate 2% cream for 7 days (n = 199) for vaginal use. Efficacy analyses included 254 patients with culture-confirmed Candida (119 butoconazole and 135 miconazole users). Of the 398 patients issued study medication, 9 were lost t...